A randomized double-blind, placebo-controlled, parallel-group, fixed single-dose regimen (SR141716 [rimonabant] 20 mg), multicenter study to assess the efficacy and safety of SR141716 in obese patients with dyslipidemia.

Trial Profile

A randomized double-blind, placebo-controlled, parallel-group, fixed single-dose regimen (SR141716 [rimonabant] 20 mg), multicenter study to assess the efficacy and safety of SR141716 in obese patients with dyslipidemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Dyslipidaemias; Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms VENUS
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Jul 2009 Actual patient number (915) added as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
    • 05 Nov 2008 Status changed from active, no longer recruiting to discontinued., as reported by sanofi-aventis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top